Josh Sommer

700 total citations
12 papers, 249 citations indexed

About

Josh Sommer is a scholar working on Rheumatology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Josh Sommer has authored 12 papers receiving a total of 249 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Josh Sommer's work include Bone Tumor Diagnosis and Treatments (10 papers), Sarcoma Diagnosis and Treatment (7 papers) and Oral and Maxillofacial Pathology (4 papers). Josh Sommer is often cited by papers focused on Bone Tumor Diagnosis and Treatments (10 papers), Sarcoma Diagnosis and Treatment (7 papers) and Oral and Maxillofacial Pathology (4 papers). Josh Sommer collaborates with scholars based in United States, United Kingdom and Italy. Josh Sommer's co-authors include Michael J. Kelley, SA Roberts, Richard Pazdur, Richard Simon, Herbert S. Schwartz, Justin Cates, Vicki L. Keedy, Silvia Stacchiotti, Daniel M. Freed and Ginger E. Holt and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Josh Sommer

12 papers receiving 243 citations

Peers

Josh Sommer

PRM

RHEUM

OS

MB

ONCOL

Tihana Rumboldt United States

Jinyeong Lim South Korea

Anna Maria Vandone Italy

Davide Mari Italy

Meng‐Zhong Liu China

José Montáns Spain

Ulrik Wallin United States

Giulia Querzoli Italy

Anders Dahlin United States

Onno van Hooij Netherlands

Tihana Rumboldt United States

Josh Sommer

32 ×0.2

PRM

19 ×0.1

RHEUM

8 ×0.1

OS

68 ×1.2

MB

58 ×1.4

ONCOL

Citations per year, relative to Josh Sommer Josh Sommer (= 1×) peers Tihana Rumboldt

Countries citing papers authored by Josh Sommer

Since Specialization

Citations

This map shows the geographic impact of Josh Sommer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josh Sommer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josh Sommer more than expected).

Fields of papers citing papers by Josh Sommer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josh Sommer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josh Sommer. The network helps show where Josh Sommer may publish in the future.

Co-authorship network of co-authors of Josh Sommer

This figure shows the co-authorship network connecting the top 25 collaborators of Josh Sommer. A scholar is included among the top collaborators of Josh Sommer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josh Sommer. Josh Sommer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Strauss, Sandra J., Silvia Stacchiotti, Irfan Kayani, et al.. (2024). A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma.. Journal of Clinical Oncology. 42(16_suppl). 11517–11517. 4 indexed citations

2.

Sharifnia, Tanaz, Mathias J. Wawer, Amy Goodale, et al.. (2023). Mapping the landscape of genetic dependencies in chordoma. Nature Communications. 14(1). 1933–1933. 17 indexed citations

3.

Dolat, Lee, et al.. (2023). Abstract 4865: Mechanisms of EGFR inhibitor sensitivity and resistance in chordoma. Cancer Research. 83(7_Supplement). 4865–4865. 1 indexed citations

4.

Kesari, Santosh, Feng Wang, Tiffany Juarez, et al.. (2023). Activity of pemetrexed in pre-clinical chordoma models and humans. Scientific Reports. 13(1). 7317–7317. 5 indexed citations

5.

Walker, Christopher J., Hua Chang, Trinayan Kashyap, et al.. (2022). Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms. Frontiers in Oncology. 12. 808021–808021. 4 indexed citations

6.

Freed, Daniel M., et al.. (2022). Emerging target discovery and drug repurposing opportunities in chordoma. Frontiers in Oncology. 12. 1009193–1009193. 6 indexed citations

7.

Dall’Agnese, Alessandra, Julien Dubrulle, Hannah L. Johnson, et al.. (2021). Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity. Cell Reports Medicine. 2(1). 100188–100188. 20 indexed citations

8.

Magnaghi, Paola, Barbara Salom, Liviana Cozzi, et al.. (2017). Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury. Molecular Cancer Therapeutics. 17(3). 603–613. 59 indexed citations

9.

Song, Paula H., Hadi Beyhaghi, Josh Sommer, & Antonia V. Bennett. (2017). Symptom burden and life challenges reported by adult chordoma patients and their caregivers. Quality of Life Research. 26(8). 2237–2244. 12 indexed citations

10.

Simon, Richard, et al.. (2015). The role of nonrandomized trials in the evaluation of oncology drugs. Clinical Pharmacology & Therapeutics. 97(5). 502–507. 49 indexed citations

11.

Xia, Menghang, Ruili Huang, Srilatha Sakamuru, et al.. (2013). Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biology & Therapy. 14(7). 638–647. 32 indexed citations

12.

Sommer, Josh, Doha Itani, Vicki L. Keedy, et al.. (2009). Methylthioadenosine phosphorylase and activated insulin‐like growth factor‐1 receptor/insulin receptor: potential therapeutic targets in chordoma. The Journal of Pathology. 220(5). 608–617. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact